HealthMode
Edit

HealthMode

http://mindmed.co/
Last activity: 06.03.2023
Categories: HealthTechLearnMachine LearningProductWellnessBioTechCareDevelopmentDrugEngineering
MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Likes
5.56K
Followers
423
Followers
811
Website visits
30K /mo.
Mentions
59
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $154.9M
Founded date: 2019

Investors 4

Funding Rounds 3

DateSeriesAmountInvestors
26.09.2022-$30M-
11.12.2020-$121.4M-
01.10.2017Seed$3.5MDCVC

Mentions in press and media 59

DateTitleDescriptionSource
19.08.2022Mind Medicine surges 78% after report reveals activist stake...Mind Medicine stock jumped as high as 78% on Thursday after a report revealed a college student acti...businessin...
08.01.2022Stephen Hurst Resigns from MindMed Board of DirectorsNEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE...marketscre...
29.12.2021MindMed Announces Transitions to Management Team- Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer...salamancap...
29.12.2021MindMed Announces Transitions to Management Team- Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer...marketscre...
29.12.2021MindMed Announces Transitions to Management Team- Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer...salamancap...
21.12.2021FDA slams clin­i­cal hold on tiny psy­che­delics play­er's s...Psy­che­del­ic ther­a­py has emerged once again as a po­ten­tial­ly promis­ing path to treat­ing neu...endpts.com...
14.12.2021MindMed Appoints Robert Barrow as Chief Executive Officer an...-Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of Mi...marketscre...
03.11.2021Psychedelics Offer Hope for Mental Disorders, AddictionNetworkNewsWire Editorial Coverage NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Global destigmatization, c...salamancap...
03.11.2021Psychedelics Offer Hope for Mental Disorders, AddictionNEW YORK, Nov. 3, 2021 /PRNewswire/ -- Global destigmatization, changing regulations and an upswing ...salamancap...
13.08.2021Mind Medicine MindMed : MindMed Announces 2021 Q2 Financial ...NEW YORK, Aug. 12, 2021 /CNW/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech c...marketscre...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In